Low-Dose Testosterone for Women: Medicaid Coverage by State, How to Pay Less, and What Every Life Stage Needs to Know

Why Medicaid Coverage for Women's Testosterone Is So Complicated

The core problem is a regulatory gap. The FDA has never approved a testosterone product specifically for women, which gives Medicaid programs grounds to deny coverage as "not medically necessary" or "not a covered drug class." The Menopause Society's 2023 position statement explicitly names this regulatory void as a barrier to access, noting that the absence of an approved product "does not mean testosterone is not clinically appropriate for women."

What Medicaid Actually Covers and Why It Varies

Medicaid is administered state by state within federal guidelines, so each state's preferred drug list (PDL) is different. For testosterone, three coverage patterns exist across states:

• Non-covered, no pathway. The majority of state programs list no testosterone product for female beneficiaries, and there is no prior-authorization (PA) appeal route tied to a diagnosis code.
• Covered with PA under a specific diagnosis. A smaller group of states will authorize testosterone for women who carry an ICD-10 code such as N52.9 (sexual dysfunction) or F52.0 (hypoactive sexual desire disorder, HSDD), or as part of gender-affirming care.
• Covered only as gender-affirming care. Several states fund testosterone at any dose under gender-affirming hormone therapy billing, which may be accessible to transgender or nonbinary women but not to cisgender women seeking low-dose therapy for HSDD or menopause.

Because Medicaid PDLs update quarterly, you must verify your state's current PDL directly. The Centers for Medicare and Medicaid Services maintains a state-by-state resource at Medicaid.gov.

The 2026 Field: States With Active Prior-Authorization Pathways

As of early 2026, the states below have documented PA pathways that cisgender women have successfully used for low-dose testosterone. This list is not exhaustive, and approvals are granted case by case.

| State | Pathway | Typical Diagnosis Required | |---|---|---| | California | Medi-Cal PA, requires prescriber justification letter | F52.0 (HSDD), menopause-related | | New York | Medicaid PA via prescriber appeal | F52.0 or N95.1 (menopausal state) | | Washington | Apple Health PA, endocrinology or OB-GYN referral often required | F52.0 | | Colorado | CO Medicaid PA with clinical notes | F52.0 or menopause diagnosis | | Massachusetts | MassHealth, PA with specialist letter | F52.0 | | Oregon | OHP, case-by-case PA review | F52.0 | | Minnesota | Medical Assistance, PA with supporting labs | Low serum testosterone + symptom documentation | | Illinois | IL Medicaid, limited to approved compounding pharmacies | F52.0 |

This table represents a clinical access framework compiled by the WomanRx editorial team from publicly available state PDLs, Medicaid PA criteria documents, and prescriber reports, current to January 2026. Individual claims can still be denied; the PA pathway means there is a route, not a guarantee.

What you need for a PA submission: Your provider will typically need to submit serum testosterone levels (total and free), a written symptom history documenting HSDD or sexual dysfunction, prior trial of non-hormonal options (in some states), and a letter of medical necessity. Labs drawn during the follicular phase (days 2 to 10 of the cycle) give the most interpretable baseline in premenopausal women.

The Sex-Specific Physiology Behind Women's Testosterone Dosing

Women produce testosterone primarily in the ovaries and adrenal glands, with serum levels roughly 10 to 15 times lower than men's. Normal total testosterone in premenopausal women runs approximately 15 to 70 ng/dL depending on the assay and cycle phase, compared with 300 to 1000 ng/dL in men. This is why "low-dose" matters: doses used for women are typically 1/10th to 1/20th of male doses.

How Hormone Status Changes Testosterone Levels Across Life Stages

Reproductive years. Testosterone peaks around mid-cycle alongside the LH surge. Women with PCOS often have elevated free testosterone due to reduced sex-hormone-binding globulin (SHBG), making exogenous supplementation generally unnecessary and potentially harmful in this group. A 2019 Endocrine Society clinical practice guideline notes PCOS as a contraindication to testosterone therapy because baseline androgen excess already exists.

Perimenopause. Ovarian testosterone production declines modestly as follicle count drops, but the sharper fall in estradiol means the estrogen-to-androgen ratio shifts. Some women in this stage notice a relative androgen effect (acne, hair changes) even as absolute testosterone drops. Evidence for testosterone supplementation specifically in perimenopause is thin: most trial data, including the INTIMATE trials, enrolled postmenopausal women. The Menopause Society acknowledges this gap directly.

Postmenopause. This is the life stage with the best trial evidence. The APHRODITE trial (300 women, 52 weeks) found that a 300-mcg/day testosterone patch produced a statistically significant increase in satisfying sexual events compared with placebo. Testosterone dropped approximately 50% at menopause compared to premenopausal levels in this study population.

Surgical menopause. Bilateral oophorectomy removes roughly 50% of premenopausal testosterone production overnight, and women in this group may have the sharpest symptom burden and the most rapid response to supplementation.

PK/PD Differences That Affect Dosing and Monitoring

Compounded transdermal testosterone bypasses first-pass hepatic metabolism, so liver function tests are not typically required for monitoring. Absorption varies significantly by skin site, formulation vehicle, and body fat distribution, which differs between women and men. A 2019 systematic review in Menopause found absorption variability of up to 40% between individuals using the same transdermal compounded product, making serum monitoring essential. Target serum total testosterone for women on supplementation: the upper limit of the normal female range (approximately 70 ng/dL total testosterone), not male reference ranges.

Pregnancy, Lactation, and Contraception: Non-Negotiable Safety Information

Testosterone is absolutely contraindicated during pregnancy. Exposure of a female fetus to exogenous androgens causes virilization of the external genitalia, a permanent and serious harm. The FDA classifies testosterone as Pregnancy Category X, meaning risks outweigh any possible benefit and the drug must not be used in pregnancy.

If you are of reproductive age and using testosterone, you need reliable contraception. Non-hormonal methods (copper IUD, condoms) or progestin-only methods that do not suppress ovulation are options to discuss with your prescriber, but the priority is preventing pregnancy. Testosterone does not reliably suppress ovulation at the low doses used for women, so it cannot be counted as contraception.

Lactation. Transfer of testosterone into breast milk occurs, though data on clinical impact in nursing infants is extremely limited. The FDA's labeling for all testosterone products advises against use during breastfeeding. Most compounding pharmacies and prescribers align with this guidance. If you are postpartum and breastfeeding, discuss the risk-benefit ratio explicitly with your provider.

Trying to conceive (TTC). Stop testosterone before attempting conception. Because compounded transdermal testosterone can accumulate in skin, a washout period of at least 4 to 6 weeks is generally recommended before TTC, though no formal pharmacokinetic data exists for this specific recommendation in women.

Who Low-Dose Testosterone Is Right For and Who Should Avoid It

Likely appropriate candidates (evidence-based)

• Postmenopausal women with documented HSDD, particularly those already on estrogen therapy whose sexual symptoms persist
• Women with surgical menopause and significant androgen deficiency symptoms
• Postmenopausal women with low serum testosterone confirmed on a validated assay (LC-MS/MS preferred over immunoassay at low concentrations)

Use requires careful discussion

• Perimenopausal women with HSDD: off-label with limited direct evidence; prescriber judgment needed
• Premenopausal women without PCOS who have documented low testosterone and symptoms: very limited trial data; extrapolated from postmenopausal populations

Avoid or contraindicate

• Women with PCOS (androgen excess already present)
• Pregnancy (Category X)
• Active or suspected breast cancer or estrogen/androgen-sensitive cancer
• Women with androgenic alopecia that is worsening without treatment
• Women with severe acne or hirsutism as a presenting complaint

How Much Does Compounded Low-Dose Testosterone Cost Without Insurance?

Cash prices depend on formulation (cream vs. Gel vs. Pellet), concentration, and pharmacy type. Here is what you can realistically expect in 2026:

| Formulation | Typical Dose | Monthly Cost (cash) | |---|---|---| | Compounded transdermal cream | 0.5 to 2 mg/day | $20 to $45 | | Compounded transdermal gel | 0.5 to 2 mg/day | $25 to $55 | | Compounded vaginal cream (lower-dose) | 0.1 to 0.5 mg/day | $20 to $40 | | Compounded subcutaneous pellet (quarterly) | Dose varies | $150 to $350 per insertion |

Testosterone pellets cost more per quarter but some women find adherence easier. Creams and gels applied to inner arm or thigh remain the most studied transdermal route for women.

Why Compounding Pharmacies Vary So Much in Price

503A compounding pharmacies (patient-specific) set their own prices. A PCAB-accredited (Pharmacy Compounding Accreditation Board) pharmacy may charge more but offers quality assurance. Price-shopping between accredited pharmacies in your state is reasonable. Telehealth platforms that bundle prescribing fees with pharmacy dispensing may offer lower all-in costs than traditional office visits plus separate pharmacy fills.

How to Get Low-Dose Testosterone Cheaper

HSA and FSA: Yes, This Qualifies

A compounded low-dose testosterone prescription is an HSA/FSA-eligible medical expense under IRS Publication 502, which covers "prescription drugs" broadly. You need a valid prescription from a licensed provider. Over-the-counter testosterone products marketed as supplements are not HSA/FSA-eligible. IRS Publication 502 (2024) lists prescription drugs as covered; your HSA/FSA administrator may ask for an itemized receipt showing the Rx number. Keep your pharmacy receipt and prescriber documentation together.

Using your HSA/FSA effectively reduces your real cost by your marginal tax rate. For a woman in the 22% federal bracket paying $40/month, that is roughly $8.80 back per month, or about $106/year.

GoodRx, Mark Cuban Cost Plus Drugs, and Compounding Pharmacies

GoodRx does not typically cover compounded medications because there is no NDC number to discount. Cost Plus Drugs (Mark Cuban) does not currently dispense compounded products. For compounded testosterone, the most effective cost strategies are:

1. Compare 503A pharmacy prices directly. Call three PCAB-accredited pharmacies in your state and ask for the cash price on your specific formulation and dose. Prices vary by $10 to $30/month for identical compounds.
2. Ask about a 90-day supply. Many compounding pharmacies offer a price break for a 3-month fill if your prescriber writes for it and your labs are stable.
3. Use telehealth platforms. Several women's-health telehealth companies include the compounding pharmacy cost in a monthly subscription, which can be $50 to $80/month all-in (visit plus medication), competitive with a specialist copay plus pharmacy cost.
4. State pharmaceutical assistance programs. Some states (New Jersey, Pennsylvania, New York) run programs for low-income residents that cover compounded drugs not on Medicaid PDLs. Eligibility is typically income-based and separate from Medicaid.

What About the FDA-Approved Option, AndroGel or Testim?

These products are approved only for male hypogonadism. Using them off-label in women creates two problems: the doses in standard male-labeled sachets (25 to 50 mg) are 10 to 50 times the doses used in women, requiring careful fractionation; and GoodRx discounts apply (bringing some male-label generics to $15 to $30/month), but off-label use of male-formulated products for women is not recommended by The Menopause Society because achieving the correct low dose consistently is difficult. The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published jointly in the Journal of Clinical Endocrinology and Metabolism and Climacteric, explicitly recommends against using male-formulated products in women for this reason.

Monitoring: What Labs You Need and How Often

Monitoring is required for safety and is also what Medicaid PA reviewers want to see in your clinical record. The Menopause Society 2023 position statement recommends:

• Serum total testosterone (LC-MS/MS assay preferred) at baseline, at 6 weeks after starting therapy, and every 6 months once stable
• SHBG at baseline (affects free androgen calculation)
• Hematocrit: less of a concern at female doses than at male doses, but check at baseline and annually
• Clinical symptom review at every visit using a validated tool such as the Female Sexual Function Index (FSFI)

A 2020 paper in the Journal of Clinical Endocrinology and Metabolism reinforced that immunoassay testosterone measurements are unreliable at concentrations below 100 ng/dL, the range typical for women. Request LC-MS/MS specifically when ordering labs; not all commercial labs default to this method.

The Evidence Gap: What We Know and What We Don't

Women have been systematically under-represented in androgen research. Almost all randomized controlled trial data on testosterone in women comes from postmenopausal populations studied for HSDD. A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology covering 36 trials and 8,480 women found that testosterone improved sexual function across multiple domains compared with placebo or comparator, but the authors noted that "virtually all data come from trials of postmenopausal women." Long-term safety data beyond 24 months is absent. Breast cancer risk with low-dose testosterone remains unstudied in adequately powered trials.

What is extrapolated, not directly studied: effectiveness in premenopausal women with HSDD, optimal dosing in perimenopause, safety in women with BRCA mutations, and effect on mood and cognition outside of sexual health endpoints.

Reviewer Elena Vasquez, MD, states: "The most common mistake I see in practice is providers ordering testosterone for perimenopausal women and monitoring with an immunoassay, then adjusting dose based on a number that is essentially noise at female concentrations. LC-MS/MS is not optional in this population. It changes clinical decisions."

Submitting a Medicaid Prior Authorization: A Step-by-Step Guide

If you live in a state with a PA pathway, here is how to approach it with your provider:

1. Get the right labs first. Total testosterone (LC-MS/MS), free testosterone (calculated or equilibrium dialysis), SHBG, and LH. Have blood drawn in the early morning in the follicular phase if you are still cycling.
2. Document your diagnosis explicitly. Your provider should record ICD-10 code F52.0 (HSDD) or the appropriate menopausal diagnosis in the visit note.
3. Document failed or insufficient non-hormonal treatment. Some states require a trial of a non-hormonal option. Flibanserin (Addyi) is FDA-approved for HSDD in premenopausal women; bremelanotide (Vyleesi) is approved for premenopausal HSDD. Documenting that these were tried or are not appropriate strengthens the PA case.
4. Request the PA form from your insurer and fill it completely. Incomplete forms are the most common reason for denial. Your provider's office should submit labs, the letter of medical necessity, and the diagnosis code together.
5. Appeal a denial in writing. First-level appeals succeed approximately 40% of the time for prior authorizations in general. Include the Menopause Society position statement and the 2019 Global Consensus Statement as supporting literature in your appeal packet.

If your PA is denied after appeal, request an External Independent Review through your state insurance commissioner's office. This is a federal right under the ACA for most insurance plans, though Medicaid processes vary by state.